LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
申请人:CAYMAN CHEMICAL COMPANY, INC.
公开号:US20160031811A1
公开(公告)日:2016-02-04
Disclosed herein are compounds of formula (I)
wherein L
1
, L
2
, L
3
, R
1
, R
4
, R
5
, and R
6
are as defined in the specification. Compounds of formula (I) are EP
4
agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
本文披露了I式化合物,其中L1、L2、L3、R1、R4、R5和R6如规范中所定义。I式化合物是EP4受体激动剂,可用于治疗青光眼、骨质疏松症、骨折、牙周骨质丢失、骨科植入物、脱发、神经病性疼痛和相关疾病。还描述了制药组合物和治疗条件或疾病的方法。